Результаты поиска

The Role of Purported Mucoprotectants in Dealing with Irritable Bowel Syndrome, Functional Diarrhea, and Other Chronic Diarrheal Disorders in Adults.

Chronic diarrhea is a frequent presenting symptom, both in primary care medicine and in specialized gastroenterology units. It is estimated that more than 5% of the global population suffers from chronic diarrhea. and that about 40% of these subjects are older than 60 years. The clinician is frequently faced with the need to decide which is the best therapeutic approach for these patients. While the origin of chronic diarrhea is diverse, impairment of intestinal barrier function, dysbiosis. and mucosal micro-inflammation are being increasingly recognized as underlying phenomena characterizing

Совпадение в полном тексте источника
… One prospective pilot study revealed that the duration of diarrhea experienced by lymphoma patients receiving melphalan chemotherapy was decreased as compared to the placebo group, while this did not happen in multiple myeloma patients irrespective of treatment [ 123 ]. …

Advances in Gold Nanoparticle-Based Combined Cancer Therapy.

According to the global cancer observatory (GLOBOCAN), there are approximately 18 million new cancer cases per year worldwide. Cancer therapies are largely limited to surgery, radiotherapy, and chemotherapy. In radiotherapy and chemotherapy, the maximum tolerated dose is presently being used to treat cancer patients. The integrated development of innovative nanoparticle (NP) based approaches will be a key to address one of the main issues in both radiotherapy and chemotherapy: normal tissue toxicity. Among other inorganic NP systems, gold nanoparticle (GNP) based systems offer the means to fur

Совпадение в полном тексте источника
… GNP: Gold Nanoparticle; PAC: Paclitaxel; TNF: Tumor Necrosis Factor; PEG: Polyethylene Glycol; DOX: Doxorubicin; BLM: Bleomycin; CIS: Cisplatin; GLC: Glucose; PDC: Peptide-drug-conjugate containing chlorambucil, melphalan, or bendamustine; 5-FU: 5-Fluorouracil; GSH: Glutathione; CS: Chitosan; RGD: arginyl-glycyl-aspartic …

The Ubiquitin-Proteasome System (UPS) as a Cancer Drug Target: Emerging Mechanisms and Therapeutics

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Combinations with Doxorubicin/Adriamycin (ADR), Thalidomide, Melphalan, Dexamethasone, Cyclophosphamide and Myriad have also been successful. The most active combination to date includes Bortezomib, Lenalidomide and Dexamethasone, where overall responses of 100 % were obtained in phase II. …

Development of Targeted Alpha Particle Therapy for Solid Tumors.

Targeted alpha-particle therapy (TAT) aims to selectively deliver radionuclides emitting α-particles (cytotoxic payload) to tumors by chelation to monoclonal antibodies, peptides or small molecules that recognize tumor-associated antigens or cell-surface receptors. Because of the high linear energy transfer (LET) and short range of alpha (α) particles in tissue, cancer cells can be significantly damaged while causing minimal toxicity to surrounding healthy cells. Recent clinical studies have demonstrated the remarkable efficacy of TAT in the treatment of metastatic, castration-resistant prosta

Совпадение в полном тексте источника
… Anti CD138 mAb conjugated with 213 Bi has been tested synergistically with the chemotherapeutic melphalan to help eliminate residual disease in a multiple myeloma model [ 116 ]. Interestingly, this study saw no benefit to the combination therapy when compared with RIT alone. …

The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Session.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

A New Paradigm for Pediatric AML: Improving the Pipeline for Treatments Targeting Cytogenetic and Molecular Alterations.

Pediatric acute myeloid leukemia (AML) is a highly heterogeneous malignancy, with cytogenetic and molecular abnormalities playing a critical role in determining prognosis and guiding treatment decisions. Despite therapeutic advances, patients with high-risk genetic mutations and translocations continue to experience suboptimal outcomes. As new targeted therapies emerge, the treatment of pediatric AML could undergo a paradigm shift, where "one-size-fits-all" chemotherapy is no longer the only frontline approach. Identifying genetic markers inform risk stratification and have greater impact on s

Совпадение в полном тексте источника
… Engineered Donor Graft (Orca Q) | HSCT Recipients in AML, ALL, MPAL or undifferentiated leukemia, CML in accelerated phase | ≤50 years | | - NCT03802695 | 1 | Orca-Q | AML, ALL, MPAL, or high/very high-risk MDS and HSCT Recipients | 12–78 years | | [ 108 ] NCT03494569 | 1 | TMLI with Fludarabine and Melphalan …

Modeling the Bone Marrow Niche in Multiple Myeloma: From 2D Cultures to 3D Systems.

Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of plasma cells within the bone marrow. The tumor microenvironment plays a crucial role in multiple myeloma pathogenesis, progression, and drug resistance. Traditional two-dimensional cell culture models have been instrumental in multiple myeloma research. However, they fail to recapitulate the complex in vivo bone marrow microenvironment, leading to limited predictive value for clinical outcomes. Three-dimensional cell culture models emerged as more physiologically relevant systems, offering enhanced insigh

Совпадение в полном тексте источника
… This is relevant for standard-of-care agents like bortezomib and melphalan, where early IC 50 values obtained in 2D systems can guide later-stage validations in more complex environments [ 39 ]. …

Клеточная терапия в многоразовом склерозе: Клинические достижения, ограничения и перспективы на будущее из клинических исследований - систематический обзор.

Фон: Множественный склероз (MS) — хроническое аутоиммунное демиелинирующее заболевание центральной нервной системы (CNS), характеризующееся воспалением, обезвоживанием и прогрессивным нейродегенерацией. Несмотря на то, что нынешняя медикаментозная терапия (ДМТ) может снизить частоту рецидивов и провокационной активности, они редко останавливают долгосрочное развитие или устраняют неврологические повреждения. В последние годы клеточная терапия стала многообещающим подходом к содействию иммунальному регулированию и нейрогенерации в MS. Методы: Настоящий обзор резюмирует текущие клинические данны

Совпадение в полном тексте источника
… AHSCT (Autologous Hematopoietic Stem Cell Transplantation), ARR (Annualized Relapse Rate), ATG (Anti-Thymocyte Globulin), BEAM (Carmustine, Etoposide, Cytarabine, Melphalan), BSBMTCT (British Society of Blood and Marrow Transplantation and Cellular Therapy), CD (Confirmed Disability), CD34+ (Hematopoietic …

Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy.

High rates of failure, exorbitant costs, and the sluggish pace of new drug discovery and development have led to a growing interest in repurposing "old" drugs to treat both common and rare diseases, particularly cancer. Cancer, a complex and heterogeneous disease, often necessitates a combination of different treatment modalities to achieve optimal outcomes. The intrinsic polygenicity of cancer, intricate biological signalling networks, and feedback loops make the inhibition of a single target frequently insufficient for achieving the desired therapeutic impact. As a result, addressing these c

Совпадение в полном тексте источника
… The use of thalidomide in combination with other drugs that are efficacious against myeloma cells was then investigated in subsequent trials which demonstrated response rate of about 50% when combined with steroids, and about 70% when combined with steroids and an alkylating agent such as melphalan [ …

Therapeutic drug monitoring for cytotoxic anticancer drugs: Principles and evidence-based practices.

Cytotoxic drugs are highly efficacious and also have low therapeutic index. A great degree of caution needs to be exercised in their usage. To optimize the efficacy these drugs need to be given at maximum tolerated dose which leads to significant amount of toxicity to the patient. The fine balance between efficacy and safety is the key to the success of cytotoxic chemotherapeutics. However, it is possibly more rewarding to obtain that balance for this class drugs as the frequency of drug related toxicities are higher compared to the other therapeutic class and are potentially life threatening

Совпадение в полном тексте источника
… Several studies conducted in different settings (different age groups like adult and children; several disease conditions like CML, AML, and multiple myeloma; and different co-conditioning agents like cyclophosphamide and melphalan) encountered similar findings ( 5 , 38 , 41 , 49 , 56 – 59 ). …

Clinical relevance of extracellular vesicles in hematological neoplasms: from liquid biopsy to cell biopsy.

In the era of precision medicine, liquid biopsy is becoming increasingly important in oncology. It consists in the isolation and analysis of tumor-derived biomarkers, including extracellular vesicles (EVs), in body fluids. EVs are lipid bilayer-enclosed particles, heterogeneous in size and molecular composition, released from both normal and neoplastic cells. In tumor context, EVs are valuable carriers of cancer information; in fact, their amount, phenotype and molecular cargo, including proteins, lipids, metabolites and nucleic acids, mirror nature and origin of parental cells rendering EVs a

Совпадение в полном тексте источника
… Of note, a clinical trial is currently ongoing in Italy to investigate the prognostic role of EVs in elderly MM patients treated with bortezomib-melphalan-prednisone or lenalidomide-desamethasone (MM, Eudract2017-004003-46). …

N-3 Long-Chain Polyunsaturated Fatty Acids, Eicosapentaenoic and Docosahexaenoic Acid, and the Role of Supplementation during Cancer Treatment: A Scoping Review of Current Clinical Evidence.

This scoping review examines the evidence for n-3 long-chain polyunsaturated fatty acid [LCPUFA, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] supplementation in clinical cancer therapy. A comprehensive literature search was performed to identify relevant clinical intervention studies conducted through August 2020. Fifty-seven unique cancer trials, assessing EPA and/or DHA supplementation pre- or post-treatment, concomitant with neoadjuvant chemotherapy, radiation or surgery, or in palliative therapy were included. Breast, head and neck, gastrointestinal, gastric, colorectal/rect

Совпадение в полном тексте источника
… 2.1/23.9 ± 2.4 | Cisplatin, ±TXT, ± Bevacizumab | 0.71 g = 0.5 g EPA/0.20 g DHA CNT = N/A | 6 weeks | N-3 group ↓ CRP, IL-6 and PGE2; NC in QOL or nutritional status | 2018 [ 51 ] Multiple Myeloma | 18 8 F/11 M | Age = 69 (57–76) | Bortezomib + Thalidomide + Dexamethasone (84 days) or Bortezomib + Melphalan …

Thrombotic microangiopathy in oncology - a review.

Thrombotic microangiopathy is a syndrome triggered by a wide spectrum of situations, some of which are specific to the Oncology setting. It is characterized by a Coombs-negative microangiopathic haemolytic anemia, thrombocytopenia and organ injury, with characteristic pathological features, resulting from platelet microvascular occlusion. TMA is rare and its cancer-related subset even more so. TMA triggered by drugs is the most common within this group, including classic chemotherapy and the latest targeted therapies. The neoplastic disease itself and hematopoietic stem-cell transplantation co

Совпадение в полном тексте источника
… High-dose carboplatin/etoposide/melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma. Bone Marrow Trans. 2018;53(10):1311–1318. doi: 10.1038/s41409-018-0159-8. 118. …

Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain.

Bone metastasis develops in multiple malignancies with a wide range of incidence. The presence of multiple bone metastases, leading to a multitude of complications and poorer prognosis. The corresponding refractory bone pain is still a challenging issue managed through multidisciplinary approaches to enhance the quality of life. Radiopharmaceuticals are mainly used in the latest courses of the disease. Bone-pain palliation with easy-to-administer radionuclides offers advantages, including simultaneous treatment of multiple metastatic foci, the repeatability and also the combination with other

Совпадение в полном тексте источника
… Giralt S., Bensinger W., Goodman M., Podoloff D., Eary J., Wendt R., Alexanian R., Weber D., Maloney D., Holmberg L. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: Results of two phase 1/2 trials. …

Donor Evaluation for Hematopoietic Stem and Progenitor Cell Collection

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Leverett D Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used Br J Haematol 2006 134 5 517 525 10.1111/j.1365-2141.2006.06223.x 17018030 Jantunen E Kuittinen T Penttilä K High-dose melphalan …

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.

The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM). Importantly, the outcome of patients continues to improve with the incorporation of this new class of agents with current MM therapies. However, both antigens are also expressed on other normal tissues including hematopoietic lineages and immune effector cells, which may limit their long-term clinical use. B cell maturation antigen (BCMA), a transme

Совпадение в полном тексте источника
… Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 359(9):906–17. 10.1056/NEJMoa0801479 7. Rosinol L, Oriol A, Teruel AI, Hernandez D, Lopez-Jimenez J, de la Rubia J, et al. …

49th ESCP virtual symposium on clinical pharmacy 19.10.2021-21.10.2021 Clinical pharmacy, working collaboratively in mental health care.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Understanding DMG: current treatment options and prospective solutions using nanoparticles.

Diffuse Midline Gliomas (DMGs), which include the subset formerly known as Diffuse Intrinsic Pontine Glioma (DIPG), are associated with an extremely poor prognosis and a five-year survival rate below 2-3%. The devastating prognosis stems from an inherently invasive nature, a deep, anatomically restricted location, rapid cellular drug efflux mediated by transporters such as P-glycoprotein (ABCB1) and breast cancer resistance protein (BCRP/ABCG2), and an immunologically "cold" microenvironment. Coupled with limited Blood-Brain Barrier (BBB) permeability, these biological factors render conventio

Совпадение в полном тексте источника
… Local drug delivery DMG Depatuxizumab Mafoditin (ABT-414) +/- Temozolomide or Lomustine NCT02343406 II PO Pediatrics Adults Targeted kinase inhibition EGFR-amplified gliomas Chemotherapy Mebendazole NCT02644291 I PO Pediatrics Targeted small-molecule therapy Pediatric gliomas Intra-arterial delivery of Melphalan … Depatuxizumab Mafoditin (ABT-414) +/- Temozolomide or Lomustine | NCT02343406 | II | PO | Pediatrics Adults | Targeted kinase inhibition | EGFR-amplified gliomas Chemotherapy Mebendazole | NCT02644291 | I | PO | Pediatrics | Targeted small-molecule therapy | Pediatric gliomas Intra-arterial delivery of Melphalan …

Mapping the function of MicroRNAs as a critical regulator of tumor-immune cell communication in breast cancer and potential treatment strategies.

Among women, breast cancer ranks as the most prevalent form of cancer, and the presence of metastases significantly reduces prognosis and diminishes overall survival rates. Gaining insights into the biological mechanisms governing the conversion of cancer cells, their subsequent spread to other areas of the body, and the immune system's monitoring of tumor growth will contribute to the advancement of more efficient and targeted therapies. MicroRNAs (miRNAs) play a critical role in the interaction between tumor cells and immune cells, facilitating tumor cells' evasion of the immune system and p

Unraveling the Anticancer Effect of Curcumin and Resveratrol.

Resveratrol and curcumin are natural products with important therapeutic properties useful to treat several human diseases, including cancer. In the last years, the number of studies describing the effect of both polyphenols against cancer has increased; however, the mechanism of action in all of those cases is not completely comprehended. The unspecific effect and the ability to interfere in assays by both polyphenols make this challenge even more difficult. Herein, we analyzed the anticancer activity of resveratrol and curcumin reported in the literature in the last 11 years, in order to unr

Совпадение в полном тексте источника
… resveratrol | cisplatin | ovarian | [ 439 ] resveratrol | cisplatin | colorectal | [ 440 ] resveratrol | 5-fluorouracil | colorectal | [ 441 ] resveratrol | 5-fluorouracil | melanoma | [ 442 ] resveratrol | doxorubicin | breast | [ 443 ] resveratrol | doxorubicin | leukemia | [ 444 ] resveratrol | melphalan …